“Title of publication” Journal, Year

Penn investigators involved (*lead)

What we learned

“Avacopan for the Treatment of ANCA-Associated Vasculitis”

New England Journal of Medicine, 2021

Dr. Peter Merkel*

- Patients who received avacopan were more likely to stay in remission versus those who were just taking prednisone

“Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis”

New England Journal of Medicine, 2020

Dr. Peter Merkel*

- Largest international clinical trial performed in AAV

- Use of plasma exchange does not improve survival or risk of end-stage renal disease

- Compared to standard doses of prednisone, a more rapid taper of prednisone is just as effective and safer (fewer serious infections)

“Characterisation of the nasal microbiota in granulomatosis with polyangiitis”

Annals of the Rheumatic Diseases, 2018

Dr. Rennie Rhee*

Dr. Peter Merkel*

Dr. Antoine Sreih

- Compared to patients without GPA, those with GPA have different types of bacteria in the nasal cavity

- Use of immunosuppression restores “healthy” bacteria

“Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire”

Annals of the Rheumatic Diseases, 2018

Dr. Peter Merkel*

- Development of new disease-specific patient-reported outcome questionnaire for use in research

“Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis”

New England Journal of Medicine, 2017

Dr. Peter Merkel*

- First clinical trial exclusively performed in patients with eosinophilic granulomatosis with polyangiitis

- Compared to prednisone alone, patients with EGPA receiving mepolizumab had more weeks in remission and were able to taper prednisone to lower doses

“Identification of functional and expression polymorphisms associated with risk for ANCA-associated vasculitis”

Arthritis & Rheumatology, 2017

Dr. Peter Merkel*

Dr. Antoine Sreih

- This study identified gene variants found which could influence clinical presentation and explain in part why disease develops